These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37850639)

  • 1. An archaeal virus-encoded anti-CRISPR protein inhibits type III-B immunity by inhibiting Cas RNP complex turnover.
    Liu J; Li Q; Wang X; Liu Z; Ye Q; Liu T; Pan S; Peng N
    Nucleic Acids Res; 2023 Nov; 51(21):11783-11796. PubMed ID: 37850639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis for inhibition of type III-B CRISPR-Cas by an archaeal viral anti-CRISPR protein.
    Lin J; Alfastsen L; Bhoobalan-Chitty Y; Peng X
    Cell Host Microbe; 2023 Nov; 31(11):1837-1849.e5. PubMed ID: 37909049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Type III CRISPR-Cas Immunity by an Archaeal Virus-Encoded Anti-CRISPR Protein.
    Bhoobalan-Chitty Y; Johansen TB; Di Cianni N; Peng X
    Cell; 2019 Oct; 179(2):448-458.e11. PubMed ID: 31564454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system.
    Pan S; Li Q; Deng L; Jiang S; Jin X; Peng N; Liang Y; She Q; Li Y
    RNA Biol; 2019 Sep; 16(9):1166-1178. PubMed ID: 31096876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CRISPR Proteins in Archaea.
    Peng X; Mayo-Muñoz D; Bhoobalan-Chitty Y; Martínez-Álvarez L
    Trends Microbiol; 2020 Nov; 28(11):913-921. PubMed ID: 32499102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance of Sulfolobus SMV1 virus to the immunity of I-A and III-B CRISPR-Cas systems in Sulfolobus islandicus.
    Guo T; Han W; She Q
    RNA Biol; 2019 Apr; 16(4):549-556. PubMed ID: 29629622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.
    Han W; Stella S; Zhang Y; Guo T; Sulek K; Peng-Lundgren L; Montoya G; She Q
    Nucleic Acids Res; 2018 Nov; 46(19):10319-10330. PubMed ID: 30239876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease.
    Sheppard NF; Glover CV; Terns RM; Terns MP
    RNA; 2016 Feb; 22(2):216-24. PubMed ID: 26647461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three CRISPR-Cas immune effector complexes coexist in Pyrococcus furiosus.
    Majumdar S; Zhao P; Pfister NT; Compton M; Olson S; Glover CV; Wells L; Graveley BR; Terns RM; Terns MP
    RNA; 2015 Jun; 21(6):1147-58. PubMed ID: 25904135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.
    Foster K; Grüschow S; Bailey S; White MF; Terns MP
    Nucleic Acids Res; 2020 May; 48(8):4418-4434. PubMed ID: 32198888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target sequence requirements of a type III-B CRISPR-Cas immune system.
    Johnson K; Learn BA; Estrella MA; Bailey S
    J Biol Chem; 2019 Jun; 294(26):10290-10299. PubMed ID: 31110048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cmr4 is the slicer in the RNA-targeting Cmr CRISPR complex.
    Zhu X; Ye K
    Nucleic Acids Res; 2015 Jan; 43(2):1257-67. PubMed ID: 25541196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-cleavage activity of Cas6b in crRNA processing of two different CRISPR-Cas systems in Methanosarcina mazei Gö1.
    Nickel L; Ulbricht A; Alkhnbashi OS; Förstner KU; Cassidy L; Weidenbach K; Backofen R; Schmitz RA
    RNA Biol; 2019 Apr; 16(4):492-503. PubMed ID: 30153081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
    Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
    Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of Target RNA Cleavage of a III-B CRISPR-Cas System Induces Robust Autoimmunity in
    Zhang Y; Lin J; Tian X; Wang Y; Zhao R; Wu C; Wang X; Zhao P; Bi X; Yu Z; Han W; Peng N; Liang YX; She Q
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A type III-B CRISPR-Cas effector complex mediating massive target DNA destruction.
    Han W; Li Y; Deng L; Feng M; Peng W; Hallstrøm S; Zhang J; Peng N; Liang YX; White MF; She Q
    Nucleic Acids Res; 2017 Feb; 45(4):1983-1993. PubMed ID: 27986854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic determinants of PAM-dependent DNA targeting and pre-crRNA processing in Sulfolobus islandicus.
    Peng W; Li H; Hallstrøm S; Peng N; Liang YX; She Q
    RNA Biol; 2013 May; 10(5):738-48. PubMed ID: 23392249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.